Circulating Matrix Metalloproteinase-9 in Chronic Heart Failure Patients Correlated With the Severity of Heart Failure and Outcome

DOI

Search this article

Description

-1.35 6 1.54 kg, 45 mg: -1.85 6 1.10 kg). However, there was no significant dosedependency in BW decrease among the tolvaptan groups. Congestive signs were improved in all tolvaptan groups. Urine volume increased dose-dependently without significant increase in sodium and potasium excretion. Adverse reactions such as thirst and dehydration occurred more frequently in the higher-dose groups. Conclusion: Tolvaptan demonstrated an aquaretic effect and clinical efficacy and safety in a dose range of 15 to 45 mg in HF patients with volume overload. The dose of 15 mg is the most recommendable dose.

Journal

Details 詳細情報について

Report a problem

Back to top